3 min read FDA Moves to End Compounded Semaglutide and Tirzepatide What It Means for Weight Loss Patients The FDA Just Proposed a Major Change to Compounded Weight Loss Drugs If you've been following the news about weight loss medications, you may have heard that the FDA announced a significant regulatory change on April 30, 2026
BPC-157 is locally acting - targets injury site through growth factor and fibroblast pathways, dosed in micrograms (250500 mcg), given twice daily
The active molecule, tirzepatide, is what dictates the biological response
Semaglutide mimics a hormone called GLP-1, which is essential in regulating appetite and food intake
Pros and Cons at a Glance GLP-1s Big, fast weight loss Improves heart outcomes in high-risk patients Suppresses appetite Side effects & high cost Risk of muscle/bone loss More loose skin with rapid loss Exercise Improves health & lifespan even without weight loss Builds muscle and bone Low risk, low cost Builds lifelong habits Slower weight loss The Best of Both Worlds It doesnt have to be either/or
Visible weight loss typically begins within the first month, with consistent loss of 12 pounds per week thereafter